Navigation Links
HIV-infected adults in Botswana respond positively to ARV therapy public treatment program

With preliminary results from a study in Botswana, Harvard School of Public Health researchers have found that people with HIV-1 subtype C in resource-poor settings, who receive antiretroviral (ARV) therapy, can achieve comparable results to those in the developed world. A fully supported health care delivery system and infrastructure help ensure this success, according to data published in November 2005 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).

More than 95 percent of HIV-infected people live in resource-poor nations -- and only a fraction of the people have access to the potentially lifesaving treatment. This study evaluated the effectiveness of combination ARV treatment in decreasing HIV disease and death. With more than one year of follow-up for clinical and laboratory outcomes and two years of follow-up for survival estimates, the majority of enrolled patients on ARV treatment experienced favorable clinical outcomes, including improved CD4 counts, decreased viral load and weight gain comparable with other successful care and treatment programs in the developed world.

"This data confirms what we are starting to see throughout the developing world. Patients will do fine regardless of social and economic status, provided the necessary infrastructure and funding are in place," said Richard Marlink, M.D., senior author of the article and professor in the Department of Immunology and Infectious Diseases at Harvard School of Public Health (HSPH).

The clinical data was collected from a public-private partnership between the Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education (BHP) and the Infectious Disease Care Clinic (IDCC) at Princess Marina Hospital and funded through Bristol-Myers Squibbs' Secure the Future initiative. Initiated in April 2001, this public sector treatment program led to the development of the Botswana's national program and provided the first clinica
'"/>

Source:Harvard School of Public Health


Page: 1 2

Related biology news :

1. Zinc supplements safe for HIV-infected children
2. Low-cost drug gaining favor for use in HIV-infected children in poor countries
3. New study shows benefit of early therapy in HIV-infected infants
4. Meth promotes spread of virus in HIV-infected users
5. H5N1 avian flu virus vaccine induces immune responses in healthy adults
6. Confidence in memory performance helps older adults remember
7. Genes affecting blood pressure change as children become adults
8. Suicide risk does not increase when adults start using antidepressants, study finds
9. One-third of adults with diabetes still dont know they have it
10. Sleep deprivation doubles risks of obesity in both children and adults
11. Brain regions do not communicate efficiently in adults with autism
Post Your Comments:
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... CITY While researching new ways to stop the ... Health Sciences Center, have discovered a compound that has ... appears in the journal Gene Regulation and Systems Biology. ... clinical trials, successfully stopped normal cells from turning into ...
... gel electrophoresis" Most teenagers wouldnt have a clue what ... Trigiano knows the protocol inside and out. When Andrew ... the University of Tennessee, was looking for an interesting ... differences in popular brands of Easter egg dyes, Trigianos ...
... will help archeologist Bill Middleton peer into the ancient ... hyperspectral data will help build the most accurate and ... state of Oaxaca, where the Zapotec people formed the ... you ask someone off the street about Mexican archeology, ...
Cached Biology News:Chemical compound prevents cancer in lab 2DNA fingerprinting simplified 2Archaeologist uses satellite imagery to explore ancient Mexico 2Archaeologist uses satellite imagery to explore ancient Mexico 3
(Date:6/30/2015)... , June 30, 2015  The Dr. Samadi Prostate Cancer ... now offering a full suite of new genetic testing methods ... biopsy, for diagnosing prostate cancer. Dr. ... genetic tests for assessing the risk and optimizing the diagnosis ... "We,re very excited to now offer these revolutionary genetic tests ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys today ... revolutionary new archwire that allows orthodontists to simultaneously apply different forces to different ... of SmartArch. “We’re thrilled about taking SmartArch one step closer to commercial availability ...
(Date:6/29/2015)... ... ... This cutting edge standard making is a madatory tool for use in high-end ... the world’s first cuvette-shaped, solid-state filter that lets metrologists and quality control personnel know ... standards, such as those made from didymium glass were only able to operate up ...
(Date:6/29/2015)... KY and Manhattan, KS (PRWEB) , ... June ... ... has acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet ... Umbilical Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as ...
Breaking Biology Technology:New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3
... Roles as Vice Chairman of The Foundry and Advisor to ForSight ... ... Labs, MENLO PARK, Calif., Sept. 4 Morgenthaler Ventures, (http://www.morgenthaler.com/ventures ... technology investments, today announced the,addition of Hank Plain as partner in ...
... PRINCETON, N.J., Sept. 4 Medarex, Inc.,(Nasdaq: MEDX ... at the Bear,Stearns 20th Annual Healthcare Conference at 9:00 ... is being held at The Grand Hyatt,New York in ... and,will be available for replay through the Webcast page ...
... Paves the Way for the Phase III Clinical ... Commercialization of THR-100 in Developing ... NV (Euronext,Brussels: THR), a biotechnology company focused on ... technology transfer to Bharat,Biotech International Limited (Hyderabad, India) ...
Cached Biology Technology:Hank Plain Joins Morgenthaler Ventures as Partner 2Hank Plain Joins Morgenthaler Ventures as Partner 3Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4
Mouse Laminin-1 MAb (Clone AL-3)...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
IEX-1 S/L (H-20)...
WIF-1 (N-20)...
Biology Products: